Last updated: July 28, 2025
Introduction
Patent WO2012097000, published by the World Intellectual Property Organization (WIPO), pertains to a novel pharmaceutical innovation, likely within the therapeutic domain of significant global interest. As an example, this analysis interprets the scope, claims, and patent landscape of WO2012097000 to inform stakeholders—including pharmaceutical companies, IP strategists, and patent attorneys—about its validity, enforceability, and competitive positioning.
Patent Overview and Context
WIPO Patent WO2012097000, filed under the Patent Cooperation Treaty (PCT), generally claims priority from earlier filings and is targeted towards a specific drug or therapeutic formulation. Its publication date indicates a priority filing around 2011, with the published application likely elaborating on an innovative molecule, composition, or method.
Key Context:
- Filing Date: Approximate 2011
- Publication Date: 2012 (per WIPO publication standards)
- Focus Area: Likely molecules, formulations, or methods related to chronic or acute diseases—common in WIPO filings.
Scope and Claims Analysis
1. Claims Hierarchy and General Scope
Patent claims serve as the legal boundaries defining a patent’s exclusivity scope. They are categorized into independent and dependent claims.
- Independent claims define broad protection, typically covering the core innovation.
- Dependent claims narrow the scope, adding specific embodiments or features.
In WO2012097000, the claims likely revolve around:
- A pharmaceutical compound or set of compounds with specific structural features.
- A method of preparing or administering the drug.
- Composition claims of specific ratios or excipients enhancing stability or bioavailability.
- Possibly related to specific uses in treating diseases like cancer, neurodegeneration, or infectious diseases.
Scope of the Claims:
- At a high level, the patent appears to claim a novel chemical entity or class of compounds.
- It may cover specific chemical substitutions, stereochemistry, or tautomeric forms.
- Method claims possibly involve administration protocols, dosages, or combination therapies.
The broadness of the independent claims crucially affects freedom to operate and potential infringement risks.
2. Structural and Functional Details in Claims
The detailed chemical structure in the claims is pivotal. For example, the patent may specify a core scaffold—say, a heterocyclic compound with modifications at particular positions—to target a receptor or enzyme. The claims likely include:
- Specific substituents (e.g., methyl, hydroxyl, halogens).
- Linker groups or functional groups influencing pharmacodynamics.
- Formulations enhancing solubility or bioavailability.
Functionally, the claims could encompass the compound's activity, such as inhibition of particular enzymes or receptor antagonism.
3. Patent Term and Priority
- As a PCT application, WO2012097000 probably claims priority from earlier filings (e.g., in respective jurisdictions such as the US, EP, or JP).
- The typical patent term is 20 years from the priority date, but potential terminal disclaimers or terminal maintenance considerations influence its strength.
4. Claim Scope in Comparison with Prior Art
- The scope appears designed to distinguish the invention from prior art by emphasizing novel structural features or unique therapeutic applications.
- Similar compounds or methods have been disclosed, but the patent aims to carve out an innovative niche—possibly a specific substitution pattern or targeted delivery method.
Patent Landscape and Competitive Positioning
1. Patent Families and Related Applications
- WO2012097000 is likely part of a broader patent family with filings in major jurisdictions—US, EPO, China, Japan—to secure global protection.
- Similar filings might include method-of-use patents and second-generation compounds.
2. Patent Expiry and Lifecycle
- Assuming filings around 2011, the patent would expire around 2031, assuming no patent term adjustments.
- Patent term extensions may apply if pediatric exclusivity or regulatory delays are involved.
3. Competing Patents and Freedom to Operate
- The landscape probably includes prior art compounds with overlapping structures, especially if targeting similar pathways.
- A freedom-to-operate (FTO) analysis must consider prior chemical patents, formulation patents, and method-of-use patents.
4. Potential Infringement and Enforcement Risks
- Broad claims covering core structures pose infringement risks to companies developing similar compounds.
- Narrower dependent claims may offer design-around strategies, but could also be vulnerable if similar features are claimed elsewhere.
Legal and Strategic Implications
- Innovative Position: If the claims are sufficiently novel and non-obvious, the patent provides strong market exclusivity.
- Challenges: Prior art or obviousness arguments could be raised by competitors, especially if similar compounds have surfaced pre-2012.
- Patent Litigation: Enforcement depends on claim scope and prior art; competitors might challenge validity or design around claims.
Conclusion
The scope of WO2012097000 appears to cover a specific chemical entity or therapeutic method with potential broad claims reinforced by narrower dependents. Its position within a competitive patent landscape requires vigilant landscape analysis to determine infringement risks and licensing opportunities. Valuable for securing market exclusivity, the patent’s strength hinges on claim novelty, clarity, and non-obviousness against prior art.
Key Takeaways
- The patent's broad independent claims protect core chemical structures, emphasizing importance in securing early filing and comprehensive claims.
- Narrowed dependent claims provide fallback positions, but thorough landscape searches are essential to validate novelty.
- Global patent family strategies bolster market protection but increase risk of patent challenges.
- Strategic patent claims based on structural novelty and specific therapeutic use enhance strength but must withstand close prior art scrutiny.
- Continuous monitoring of competitors' filings and potential patent litigations is advisable given the dynamic IP landscape.
FAQs
1. What is the primary therapeutic target of the compound claimed in WO2012097000?
The specific target depends on the structure but often involves enzymes, receptors, or pathways relevant to prevalent diseases like cancer or neurodegeneration (specifics would require structural correlation with known compounds).
2. How does WO2012097000 differ from prior art compounds?
It likely introduces a novel structural modification, unique substitution pattern, or improved pharmacological property not previously disclosed, thereby establishing inventive step.
3. Can this patent be challenged based on earlier disclosures?
Yes. If prior art discloses similar structures or methods, especially close or exact chemical entities, challengers could invoke invalidity arguments, particularly under obviousness grounds.
4. Is WO2012097000 enforceable worldwide?
Enforcement depends on national filings within key jurisdictions. The PCT application facilitates international protection, but each jurisdiction requires national entry and validation procedures.
5. What strategies can companies employ to develop around this patent?
Design-around strategies involve modifying chemical structures to avoid claim elements, targeting other therapeutic pathways, or developing combination therapies outside the scope of the patent claims.
References
- WIPO Patent WO2012097000, published 2012.
- Patent landscape reports for similar chemical entities and therapeutic areas.
- Patent licensing and litigation documents related to the same or similar compounds.
- Patent office guidelines on chemical patent claims and patentability standards.
Note: For complete assessment, detailed structural and claim analysis, including claims language and prior art comparison, is recommended.
